Sirona Biochem Corp. (TSX-V: SBM), a biotechnology company specializing in therapeutics for diabetes and obesity, has obtained the final acceptance of the TSX Venture Exchange for the definitive agreement to acquire TFChem...
To Read This Article, Please Login or Subscribe
For $5 plus HST a month (recurring), you will have access to all our premium contents (database access is not included). For database subscription, please click here.
